RecruitingNCT04638621

Dilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Ancillary Study

Precision Medicine for Dilated Cardiomyopathy-Cardiac Magnetic Resonance to Identify Early Family Phenotypes


Sponsor

Ohio State University

Enrollment

650 participants

Start Date

Apr 1, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

The Dilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Study is an ancillary study from the parent study, DCM Precision Medicine Study. The rationale for the DCM-CMR study is to leverage cardiac magnetic resonance (CMR) imaging to detect earliest findings of DCM in the at-risk family members enrolled into the parent study.


Eligibility

Min Age: 18 Years

Inclusion Criteria11

  • The FDR's proband was enrolled in the DCM Precision Medicine Study at 1 of 9 participating sites, or exceptions granted by study PI.
  • The FDR's proband has had one or more variants identified, including P, LP and VUS.
  • The FDR is able report to one of the participating sites for study enrollment.
  • The FDR has no current contraindication for CMR (glomerular filtration rate (GFR) <30 mL/min/1.73 m2, non-compatible device implant, or allergy to gadolinium contrast).
  • The FDR has had no prior heart transplant.
  • The FDR is ≥18 years of age.
  • All races/ethnicity
  • Ability to give informed consent.
  • Ability to communicate in English.
  • Subject is not pregnant (CMR may be conducted 3-6 months post delivery)
  • Willingness to participate in a family-based study (subject willing to interact with OSU).

Exclusion Criteria8

  • Coronary artery disease (CAD) causing ischemic cardiomyopathy (> 50% narrowing, any major epicardial coronary artery).
  • Primary valvular disease.
  • Adriamycin or other cardiotoxic drug exposure.
  • Other forms of cardiomyopathy: Hypertrophic, Restrictive, or Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy.
  • Congenital heart disease.
  • Other detectable causes of dilated cardiomyopathy, including sarcoid and hemochromatosis.
  • Other active multisystem disease, even if very rare, that may plausibly cause DCM (e.g., hypereosinophilic syndrome, cardiac involvement with connective tissue disease, Loeffler's endocarditis, endomyocardial fibrosis, etc) are excluded. Please call the PI to discuss if uncertain or not clear.
  • Severe and untreated or untreatable hypertension (systolic blood pressures routinely greater than 180 mm Hg and/or diastolic blood pressures greater than 120 mm Hg, and if resistant to multidrug treatment). This includes profound hypertension associated with other multisystem disease (e.g., scleroderma, other vasculitides, etc).

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

The Ohio State University

Columbus, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04638621


Related Trials